| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Argininosuccinic acid is the natural substrate for argininosuccinate lyase (ASL), an enzyme in the urea cycle. The disodium salt form is used in research to study this enzyme and the urea cycle. Argininosuccinic acid can reduce GSH concentration and increase ROS production in the brain.
|
|---|---|
| ln Vitro |
In vitro, argininosuccinic acid reduces the concentration of reduced glutathione (GSH) and increases the production of reactive oxygen species in the brain cortex and striatum. It also causes lipid peroxidation and protein oxidation.
|
| ln Vivo |
In vivo, argininosuccinic acid is an endogenous metabolite involved in the urea cycle. Its accumulation is associated with argininosuccinic aciduria, a rare inherited disorder of the urea cycle. The compound is not administered as a therapeutic agent.
|
| Enzyme Assay |
Cell-free assays for argininosuccinic acid involve measuring the activity of argininosuccinate lyase (ASL) using the compound as a substrate. The enzyme catalyzes the cleavage of argininosuccinic acid into arginine and fumarate, and the products are measured using chromatographic or spectrophotometric methods.
|
| Cell Assay |
In vitro cellular assays for argininosuccinic acid involve treating cells with the compound and measuring its effects on GSH levels and ROS production. This is used to study the cellular effects of argininosuccinic acid accumulation in urea cycle disorders.
|
| Animal Protocol |
In vivo animal studies for argininosuccinic acid are not typically performed, as the compound is an endogenous metabolite. However, animal models of argininosuccinic aciduria are used to study the pathophysiology of this disorder and to test potential therapies.
|
| ADME/Pharmacokinetics |
The pharmacokinetics of argininosuccinic acid are not relevant, as it is an endogenous metabolite. In argininosuccinic aciduria, the compound accumulates in the blood and urine due to a deficiency of ASL.
|
| Toxicity/Toxicokinetics |
Argininosuccinic acid is not associated with toxicity at normal physiological levels. However, its accumulation in argininosuccinic aciduria leads to hyperammonemia and neurological symptoms.
|
| References | |
| Additional Infomation |
Argininosuccinic acid disodium is a research compound with no clinical applications or regulatory approvals. It is used as a tool to study the urea cycle and argininosuccinic aciduria, a rare inherited metabolic disorder. Its ability to reduce GSH and increase ROS makes it a subject of interest in oxidative stress research.
|
| Molecular Formula |
C10H16N4NA2O6
|
|---|---|
| Molecular Weight |
334.24
|
| Exact Mass |
354.113
|
| CAS # |
918149-29-8
|
| Related CAS # |
Argininosuccinic acid;2387-71-5
|
| PubChem CID |
16218930
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
22
|
| Complexity |
386
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C(C[C@@H](C(=O)[O-])N)CN=C(N)N[C@@H](CC(=O)[O-])C(=O)O.[Na+].[Na+]
|
| InChi Key |
NIOYXHIHRCWMMB-USPAICOZSA-L
|
| InChi Code |
InChI=1S/C10H18N4O6.2Na/c11-5(8(17)18)2-1-3-13-10(12)14-6(9(19)20)4-7(15)16;;/h5-6H,1-4,11H2,(H,15,16)(H,17,18)(H,19,20)(H3,12,13,14);;/q;2*+1/p-2/t5-,6-;;/m0../s1
|
| Chemical Name |
disodium;(2S)-2-amino-5-[[amino-[[(1S)-1-carboxy-2-carboxylatoethyl]amino]methylidene]amino]pentanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9919 mL | 14.9593 mL | 29.9186 mL | |
| 5 mM | 0.5984 mL | 2.9919 mL | 5.9837 mL | |
| 10 mM | 0.2992 mL | 1.4959 mL | 2.9919 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
